|
|
Myasthenia Gravis Research Highlights: AAN 2024
This accredited CME program highlights the latest clinical research about myasthenia gravis, a rare, autoimmune disease that targets the neuromuscular junction.
Treatment of myasthenia gravis is highly individualized and depends greatly on the myasthenia gravis subtype of each patient as well as each patient’s comorbidities. There are currently five drugs approved by the FDA, eculizumab, efgartigimod, ravulizumab, rozanolixizumab, and zilucoplan. Clinical trial data on these therapies, as... |
|
|
Myasthenia Gravis Research Highlights: AAN 2024
Target Audience
This activity has been designed to meet the educational needs of physicians specializing in neurology, ophthalmology and family practice. Other members of the care team may also participate.
Program Overview
This accredited CME program highlights the latest clinical research about myasthenia gravis, a rare, autoimmune disease that targets the neuromuscular junction.
Treatment of myasthenia gravis is highly individualized and depends greatly on the myasthenia gravis subt... |
|
|
FcRn and Myasthenia Gravis
Target Audience
This activity has been designed to meet the educational needs of physicians specializing in neurology and ophthalmology who may be involved in the diagnosis and care of individuals with MG. Other healthcare providers, including neurology NPs and PAs, may also participate.
Program Overview
This 30-minute CME program discusses how the FcRn system can impact myasthenia gravis and how FcRn antagonists can be used to treat this rare condition.
Learning Objectives
After part... |
|